Emerging roles of heterogeneous nuclear ribonucleoprotein K (hnRNP K) in cancer progression

Cancer Letters

Volumn 352, Issue 2, 2014, Pages 152-159

  Barboro, Paola ^a   Ferrari, Nicoletta ^a   Balbi, Cecilia ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Carcinogenesis; Heterogeneous nuclear ribonucleoprotein K; Prognostic biomarker

Indexed keywords

HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN K; MESSENGER RNA; UNTRANSLATED RNA;

CANCER CELL; CANCER GROWTH; CANCER PROGNOSIS; CARCINOGENESIS; COLORECTAL CANCER; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; HUMAN; LIVER CELL CARCINOMA; LUNG CANCER; MELANOMA; MOUTH SQUAMOUS CELL CARCINOMA; NASOPHARYNX CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CARCINOMA; PROTEIN DNA INTERACTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; RNA SPLICING; RNA STABILITY; RNA TRANSLATION; SHORT SURVEY; TRANSCRIPTION REGULATION; UPREGULATION;

CARCINOGENESIS; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN K; PROGNOSTIC BIOMARKER;

ANIMALS; CELL NUCLEUS; CELL TRANSFORMATION, NEOPLASTIC; CYTOPLASM; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEIN K; HUMANS; NEOPLASMS; PROGNOSIS; TRANSCRIPTION, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84906054100     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.06.019     Document Type: Review

References (103)

1. Dejgaard K., Leffers H., Rasmussen H.H., Madsen P., Kruse T.A., Gesser B., Nielsen H., Celis J.E. Identification, molecular cloning, expression and chromosome mapping of a family of transformation upregulated hnRNP-K proteins derived by alternative splicing. J. Mol. Biol. 1994, 236:33-48.
2. Dreyfuss G., Matunis M.J., Piñol-Roma S., Burd C.G. HnRNP proteins and the biogenesis of mRNA. Annu. Rev. Biochem. 1993, 62:289-321.
3. Piñol-Roma S., Choi Y.D., Matunis M.J., Dreyfuss G. Immunopurification of heterogeneous nuclear ribonucleoprotein particles reveals an assortment of RNA-binding proteins. Genes Dev. 1988, 2:215-227.
4. Swanson M.S., Dreyfuss G. Classification and purification of proteins of heterogeneous nuclear ribonucleoprotein particles by RNA-binding specificities. Mol. Cell. Biol. 1988, 8:2237-2241.
5. Siomi H., Matunis M.J., Michael W.M., Dreyfuss G. The pre-mRNA binding K protein contains a novel evolutionarily conserved motif. Nucleic Acids Res. 1993, 21:1193-1198.
6. Makeyev A.V., Liebhaber S.A. The poly(C)-binding proteins: a multiplicity of functions and a search for mechanisms. RNA 2002, 8:265-278.
7. Chkheidze A.N., Liebhaber S.A. A novel set of nuclear localization signals determine distributions of the αCP RNA-binding proteins. Mol. Cell. Biol. 2003, 23:8405-8415.
8. Michael W.M., Eder P.S., Dreyfuss G. The K nuclear shuttling domain: a novel signal for nuclear import and nuclear export in the hnRNP K protein. EMBO J. 1997, 16:3587-3598.
9. Yusuf D., Butland S.L., Swanson M.I., Bolotin E., Ticoll A., et al. The transcription factor encyclopedia. Genome Biol. 2012, 13:R24.
10. Leopoldino A.M., Carregaro F., Silva C.H., Feitosa O., Mancini U.M., Freitas J.M., Tajara E.H. Sequence and transcriptional study of HNRPK pseudogenes, and expression and molecular modeling analysis of hnRNP K isoforms. Genome 2007, 50:451-462.
11. Kimura Y., Nagata K., Suzuki N., Yokoyama R., Yamanaka Y., Kitamura H., Hirano H., Ohara O. Characterization of multiple alternative forms of heterogeneous nuclear ribonucleoprotein K by phosphate-affinity electrophoresis. Proteomics 2010, 10:3884-3895.
12. Ostareck-Lederer A., Ostareck D.H., Rucknagel K.P., Schierhorn A., Moritz B., Huttelmaier S., Flach N., Handoko L., Wahle E. Asymmetric arginine dimethylation of heterogeneous nuclear ribonucleoprotein K by protein-arginine methyltransferase 1 inhibits its interaction with c-Src. J. Biol. Chem. 2006, 281:11115-11125.
13. Chiou Y.Y., Lin W.J., Fu S.L., Lin C.H. Direct mass-spectrometric identification of Arg296 and Arg299 as the methylation sites of hnRNP K protein for methyltransferase PRMT1. Protein J. 2007, 26:87-93.
14. Chang Y.I., Hsu S.C., Chau G.Y., Huang C.Y., Sung J.S., Hua W.K., Lin W.J. Identification of the methylation preference region in heterogeneous nuclear ribonucleoprotein K by protein arginine methyltransferase 1 and its implication in regulating nuclear/cytoplasmic distribution. Biochem. Biophys. Res. Commun. 2011, 404:865-869.
15. Chen Y., Zhou X., Liu N., Wang C., Zhang L., Mo W., Hu G. Arginine methylation of hnRNP K enhances p53 transcriptional activity. FEBS Lett. 2008, 582:1761-1765.
16. Pelisch F., Pozzi B., Risso G., Muñoz M.J., Srebrow A. DNA damage-induced heterogeneous nuclear ribonucleoprotein K SUMOylation regulates p53 transcriptional activation. J. Biol. Chem. 2012, 287:30789-30799.
17. Lee S.W., Lee M.H., Park J.H., Kang S.H., Yoo H.M., Ka S.H., Oh Y.M., Jeon Y.J., Chung C.H. SUMOylation of hnRNP-K is required for p53-mediated cell-cycle arrest in response to DNA damage. EMBO J. 2012, 31:4441-4452.
18. Van Seuningen I., Ostrowski J., Bustelo X.R., Sleath P.R., Bomsztyk K. The K protein domain that recruits the interleukin 1-responsive K protein kinase lies adjacent to a cluster of c-Src and Vav SH3-binding sites. Implications that K protein acts as a docking platform. J. Biol. Chem. 1995, 270:26976-26985.
19. Ostrowski J., Kawata Y., Schullery D.S., Denisenko O.N., Higaki Y., Abrass C.K., Bomsztyk K. Insulin alters heterogeneous nuclear ribonucleoprotein K protein binding to DNA and RNA. Proc. Natl. Acad. Sci. USA 2001, 98:9044-9049.
20. Ostrowski J., Schullery D.S., Denisenko O.N., Higaki Y., Watts J., Aebersold R., Stempka L., Gschwendt M., Bomsztyk K. Role of tyrosine phosphorylation in the regulation of the interaction of heterogenous nuclear ribonucleoprotein K protein with its protein and RNA partners. J. Biol. Chem. 2000, 275:3619-3628.
21. Bomsztyk K., Denisenko O., Ostrowski J. HnRNP K: one protein multiple processes. BioEssays 2004, 26:629-638.
22. Habelhah H., Shah K., Huang L., Ostareck-Lederer A., Burlingame A.L., Shokat K.M., Hentze M.W., Ronai Z. ERK phosphorylation drives cytoplasmic accumulation of hnRNP-K and inhibition of mRNA translation. Nat. Cell. Biol. 2001, 3:325-330.
23. Habelhah H., Shah K., Huang L., Burlingame A.L., Shokat K.M., Ronai Z. Identification of new JNK substrate using ATP pocket mutant JNK and a corresponding ATP analogue. J. Biol. Chem. 2001, 276:18090-18095.
24. Schullery D.S., Ostrowski J., Denisenko O.N., Stempka L., Shnyreva M., Suzuki H., Gschwendt M., Bomsztyk K. Regulated interaction of protein kinase Cδ with the heterogeneous nuclear ribonucleoprotein K protein. J. Biol. Chem. 1999, 274:15101-15109.
25. Pino I., Pío R., Toledo G., Zabalegui N., Vicent S., Rey N., Lozano M.D., Torre W., García-Foncillas J., Montuenga L.M. Altered patterns of expression of members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family in lung cancer. Lung Cancer 2003, 41:131-143.
26. Ostrowski J., Bomsztyk K. Nuclear shift of hnRNP K protein in neoplasms and other states of enhanced cell proliferation. Br. J. Cancer 2003, 89:1493-1501.
27. Ostrowski J., Kawata Y., Schullery D.S., Denisenko O.N., Bomsztyk K. Transient recruitment of the hnRNP K protein to inducibly transcribed gene loci. Nucleic Acids Res. 2003, 31:3954-3962.
28. Denisenko O.N., Bomsztyk K. The product of the murine homolog of the Drosophila extra sex combs gene displays transcriptional repressor activity. Mol. Cell. Biol. 1997, 17:4707-4717.
29. Shnyreva M., Schullery D.S., Suzuki H., Higaki Y., Bomsztyk K. Interaction of two multifunctional proteins. Heterogeneous nuclear ribonucleoprotein K and Y-box-binding protein. J. Biol. Chem. 2000, 275:15498-15503.
30. Samuel S.K., Spencer V.A., Bajno L., Sun J.M., Holth L.T., Oesterreich S., Davie J.R. In situ cross-linking by cisplatin of nuclear matrix-bound transcription factors to nuclear DNA of human breast cancer cells. Cancer Res. 1998, 58:3004-3008.
31. Barboro P., D'Arrigo C., Diaspro A., Mormino M., Alberti I., Parodi S., Patrone E., Balbi C. Unraveling the organization of the internal nuclear matrix: RNA-dependent anchoring of NuMA to a lamin scaffold. Exp. Cell Res. 2002, 279:202-218.
32. Barboro P., D'Arrigo C., Mormino M., Coradeghini R., Parodi S., Patrone E., Balbi C. An intranuclear frame for chromatin compartmentalization and higher-order folding. J. Cell. Biochem. 2003, 88:113-120.
33. Barboro P., D'Arrigo C., Repaci E., Bagnasco L., Orecchia P., Carnemolla B., Patrone E., Balbi C. Proteomic analysis of the nuclear matrix in the early stages of rat liver carcinogenesis: identification of differentially expressed and MAR-binding proteins. Exp. Cell Res. 2009, 315:226-239.
34. Barboro P., Repaci E., D'Arrigo C., Balbi C. The role of nuclear matrix proteins binding to matrix attachment regions (MARs) in prostate cancer cell differentiation. PLoS ONE 2012, 7:e40617.
35. Saitoh N., Spahr C.S., Patterson S.D., Bubulya P., Neuwald A.F., Spector D.L. Proteomic analysis of interchromatin granule clusters. Mol. Biol. Cell 2004, 15:3876-3890.
36. Marenduzzo D., Faro-Trindade I., Cook P.R. What are the molecular ties that maintain genomic loops?. Trends Genet. 2007, 23:126-133.
37. Choi H.S., Hwang C.K., Song K.Y., Law P.Y., Wei L.N., Loh H.H. Poly(C)-binding proteins as transcriptional regulators of gene expression. Biochem. Biophys. Res. Commun. 2009, 380:431-436.
38. Michelotti E.F., Michelotti G.A., Aronsohn A.I., Levens D. Heterogeneous nuclear ribonucleoprotein K is a transcription factor. Mol. Cell. Biol. 1996, 16:2350-2360.
39. Denisenko O.N., O'Neill B., Ostrowski J., Van Seuningen I., Bomsztyk K. Zik1, a transcriptional repressor that interacts with the heterogeneous nuclear ribonucleoprotein particle K protein. J. Biol. Chem. 1996, 271:27701-27706.
40. Choi H.S., Song K.Y., Hwang C.K., Kim C.S., Law P.Y., Wei L.N., Loh H.H. A proteomics approach for identification of single strand DNA-binding proteins involved in transcriptional regulation of mouse μ opioid receptor gene. Mol. Cell. Proteomics 2008, 7:1517-1529.
41. Lynch M., Chen L., Ravitz M.J., Mehtani S., Korenblat K., Pazin M.J., Schmidt E.V. HnRNP K binds a core polypyrimidine element in the eukaryotic translation initiation factor 4E (eIF4E) promoter, and its regulation of eIF4E contributes to neoplastic transformation. Mol. Cell. Biol. 2005, 25:6436-6453.
42. Du Q., Melnikova I.N., Gardner P.D. Differential effects of heterogeneous nuclear ribonucleoprotein K on Sp1- and Sp3-mediated transcriptional activation of a neuronal nicotinic acetylcholine receptor promoter. J. Biol. Chem. 1998, 273:19877-19883.
43. Lau J.S., Baumeister P., Kim E., Roy B., Hsieh T.Y., Lai M., Lee A.S. Heterogeneous nuclear ribonucleoproteins as regulators of gene expression through interactions with the human thymidine kinase promoter. J. Cell. Biochem. 2000, 79:395-406.
44. Da Silva N., Bharti A., Shelley C.S. HnRNP-K and Purα act together to repress the transcriptional activity of the CD43 gene promoter. Blood 2002, 100:3536-3544.
45. Skalweit A., Doller A., Huth A., Kähne T., Persson P.B., Thiele B.J. Posttranscriptional control of renin synthesis: identification of proteins interacting with renin mRNA 3'-untranslated region. Circ. Res. 2003, 92:419-427.
46. Expert-Bezançon A., Le Caer J.P., Marie J. Heterogeneous nuclear ribonucleoprotein (hnRNP) K is a component of an intronic splicing enhancer complex that activates the splicing of the alternative exon 6A from chicken β-tropomyosin pre-mRNA. J. Biol. Chem. 2002, 277:16614-16623.
47. Cao W., Razanau A., Feng D., Lobo V.G., Xie J. Control of alternative splicing by forskolin through hnRNP K during neuronal differentiation. Nucleic Acids Res. 2012, 40:8059-8071.
48. Venables J.P., Koh C.S., Froehlich U., Lapointe E., Couture S., Inkel L., Bramard A., Paquet E.R., Watier V., Durand M., Lucier J.F., Gervais-Bird J., Tremblay K., Prinos P., Klinck R., Elela S.A., Chabot B. Multiple and specific mRNA processing targets for the major human hnRNP proteins. Mol. Cell. Biol. 2008, 28:6033-6043.
49. S splice isoform. J. Biol. Chem. 2009, 284:21458-21467.
50. Cyphert T.J., Suchanek A.L., Griffith B.N., Salati L.M. Starvation actively inhibits splicing of glucose-6-phosphate dehydrogenase mRNA via a bifunctional ESE/ESS element bound by hnRNP K. Biochim. Biophys. Acta 1829, 2013:905-915.
51. Bomsztyk K., Van Seuningen I., Suzuki H., Denisenko O., Ostrowski J. Diverse molecular interaction of the hnRNP K protein. FEBS Lett. 1997, 403:113-115.
52. Evans J.R., Mitchell S.A., Spriggs K.A., Ostrowski J., Bomsztyk K., Ostarek D., Willis A.E. Members of the poly (rC) binding protein family stimulate the activity of the c-myc internal ribosome entry segment in vitro and in vivo. Oncogene 2003, 22:8012-8020.
53. Collier B., Goobar-Larsson L., Sokolowski M., Schwartz S. Translational inhibition in vitro of human papillomavirus type 16 L2 mRNA mediated through interaction with heterogenous ribonucleoprotein K and poly(rC)-binding proteins 1 and 2. J. Biol. Chem. 1998, 273:22648-22656.
54. Yano M., Okano H.J., Okano H. Involvement of Hu and heterogeneous nuclear ribonucleoprotein K in neuronal differentiation through p21 mRNA post-transcriptional regulation. J. Biol. Chem. 2005, 280:12690-12699.
55. Ostareck-Lederer A., Ostareck D.H. Control of mRNA translation and stability in haematopoietic cells: the function of hnRNPs K and E1/E2. Biol. Cell 2004, 96:407-411.
56. Ostareck D.H., Ostareck-Lederer A., Wilm M., Thiele B.J., Mann M., Hentze M.W. mRNA silencing in erythroid differentiation: hnRNP K and hnRNP E1 regulate 15-lipoxygenase translation from the 3' end. Cell 1997, 89:597-606.
57. Naarmann I.S., Harnisch C., Flach N., Kremmer E., Kühn H., Ostareck D.H., Ostareck-Lederer A. mRNA silencing in human erythroid cell maturation: heterogeneous nuclear ribonucleoprotein K controls the expression of its regulator c-Src. J. Biol. Chem. 2008, 283:18461-18472.
58. Ostareck-Lederer A., Ostareck D.H., Cans C., Neubauer G., Bomsztyk K., Superti-Furga G., Hentze M.W. C-Src-mediated phosphorylation of hnRNP K drives translational activation of specifically silenced mRNAs. Mol. Cell. Biol. 2002, 22:4535-4543.
59. Messias A.C., Harnisch C., Ostareck-Lederer A., Sattler M., Ostareck D.H. The DICE-binding activity of KH domain 3 of hnRNP K is affected by c-Src-mediated tyrosine phosphorylation. J. Mol. Biol. 2006, 361:470-481.
60. Takimoto M., Tomonaga T., Matunis M., Avigan M., Krutzsch H., Dreyfuss G., Levens D. Specific binding of heterogeneous ribonucleoprotein particle protein K to the human c-myc promoter, in vitro. J. Biol. Chem. 1993, 268:18249-18258.
61. Mandal M., Vadlamudi R., Nguyen D., Wang R.A., Costa L., Bagheri-Yarmand R., Mendelsohn J., Kumar R. Growth factors regulate heterogeneous nuclear ribonucleoprotein K expression and function. J. Biol. Chem. 2001, 276:9699-9704.
62. Nagano K., Masters J.R., Akpan A., Yang A., Corless S., Wood C., Hastie C., Zvelebil M., Cramer R., Naaby-Hansen S. Differential protein synthesis and expression levels in normal and neoplastic human prostate cells and their regulation by type I and II interferons. Oncogene 2004, 23:1693-1703.
63. Wen F., Shen A., Shanas R., Bhattacharyya A., Lian F., Hostetter G., Shi J. Higher expression of the heterogeneous nuclear ribonucleoprotein K in melanoma. Ann. Surg. Oncol. 2010, 17:2619-2627.
64. Notari M., Neviani P., Santhanam R., Blaser B.W., Chang J.S., Galietta A., Willis A.E., Roy D.C., Caligiuri M.A., Marcucci G., Perrotti D. A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation. Blood 2006, 107:2507-2516.
65. Perrotti D., Neviani P. From mRNA metabolism to cancer therapy: chronic myelogenous leukemia shows the way. Clin. Cancer Res. 2007, 13:1638-1642.
66. Sawyers C.L., Callahan W., Witte O.N. Dominant negative MYC blocks transformation by ABL oncogenes. Cell 1992, 70:901-910.
67. Levine A.J., Oren M. The first 30 years of p53: growing ever more complex. Nat. Rev. Cancer 2009, 9:749-758.
68. Moumen A., Masterson P., O'Connor M.J., Jackson S.P. HnRNP K: an HDM2 target and transcriptional coactivator of p53 in response to DNA damage. Cell 2005, 123:1065-1078.
69. Moumen A., Magill C., Dry K.L., Jackson S.P. ATM-dependent phosphorylation of heterogeneous nuclear ribonucleoprotein K promotes p53 transcriptional activation in response to DNA damage. Cell Cycle 2013, 12:698-704.
70. Xiao Z., Ko H.L., Goh E.H., Wang B., Ren E.C. hnRNP K suppresses apoptosis independent of p53 status by maintaining high levels of endogenous caspase inhibitor. Carcinogenesis 2013, 34:1458-1467.
71. Ling H., Fabbri M., Calin G.A. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat. Rev. Drug. Discov. 2013, 12:847-865.
72. Huarte M., Guttman M., Feldser D., Garber M., Koziol M.J., Kenzelmann-Broz D., Khalil A.M., Zuk O., Amit I., Rabani M., Attardi L.D., Regev A., Lander E.S., Jacks T., Rinn J.L. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell 2010, 142:409-419.
73. Barsotti A.M., Prives C. Noncoding RNAs: the missing "linc" in p53-mediated repression. Cell 2010, 142:358-360.
74. Kim K., Choi J., Heo K., Kim H., Levens D., Kohno K., Johnson E.M., Brock H.W., An W. Isolation and characterization of a novel H1.2 complex that acts as a repressor of p53-mediated transcription. J. Biol. Chem. 2008, 283:9113-9126.
75. Gumireddy K., Li A., Yan J., Setoyama T., Johannes G.J., Orom U.A., Tchou J., Liu Q., Zhang L., Speicher D.W., Calin G.A., Huang Q. Identification of a long non-coding RNA-associated RNP complex regulating metastasis at the translational step. EMBO J. 2013, 32:2672-2684.
76. Qin A.Y., Zhang X.W., Liu L., Yu J.P., Li H., Wang S.Z., Ren X.B., Cao S. MiR-205 in cancer: an angel or a devil?. Eur. J. Cell Biol. 2013, 92:54-60.
77. Szczyrba J., Nolte E., Hart M., Döll C., Wach S., Taubert H., Keck B., Kremmer E., Stöhr R., Hartmann A., Wieland W., Wullich B., Grässer F.A. Identification of ZNF217, hnRNP-K, VEGF-A and IPO7 as targets for microRNAs that are downregulated in prostate carcinoma. Int. J. Cancer 2013, 132:775-784.
78. Barboro P., Repaci E., Rubagotti A., Salvi S., Boccardo S., Spina B., Truini M., Introini C., Puppo P., Ferrari N., Carmignani G., Boccardo F., Balbi C. Heterogeneous nuclear ribonucleoprotein K: altered pattern of expression associated with diagnosis and prognosis of prostate cancer. Br. J. Cancer 2009, 100:1608-1616.
79. Szczyrba J., Löprich E., Wach S., Jung V., Unteregger G., Barth S., Grobholz R., Wieland W., Stöhr R., Hartmann A., Wullich B., Grässer F. The microRNA profile of prostate carcinoma obtained by deep sequencing. Mol. Cancer Res. 2010, 8:529-538.
80. Carpenter B., McKay M., Dundas S.R., Lawrie L.C., Telfer C., Murray G.I. Heterogeneous nuclear ribonucleoprotein K is over expressed, aberrantly localised and is associated with poor prognosis in colorectal cancer. Br. J. Cancer 2006, 95:921-927.
81. Wang F., Zhang P., Shi C., Yang Y., Qin H. Immunohistochemical detection of HSP27 and hnRNP K as prognostic and predictive biomarkers for colorectal cancer. Med. Oncol. 2012, 29:1780-1788.
82. Roychoudhury P., Chaudhuri K. Evidence for heterogeneous nuclear ribonucleoprotein K overexpression in oral squamous cell carcinoma. Br. J. Cancer 2007, 97:574-575.
83. Matta A., Tripathi S.C., DeSouza L.V., Grigull J., Kaur J., Chauhan S.S., Srivastava A., Thakar A., Shukla N.K., Duggal R., DattaGupta S., Ralhan R., Michael Siu K.W. Heterogeneous ribonucleoprotein K is a marker of oral leukoplakia and correlates with poor prognosis of squamous cell carcinoma. Int. J. Cancer 2009, 125:1398-1406.
84. Wu C.S., Chang K.P., Chen L.C., Chen C.C., Liang Y., Hseuh C., Chang Y.S. Heterogeneous ribonucleoprotein K and thymidine phosphorylase are independent prognostic and therapeutic markers for oral squamous cell carcinoma. Oral Oncol. 2012, 48:516-522.
85. Hatakeyama H., Kondo T., Fujii K., Nakanishi Y., Kato H., Fukuda S., Hirohashi S. Protein clusters associated with carcinogenesis, histological differentiation and nodal metastasis in esophageal cancer. Proteomics 2006, 6:6300-6316.
86. Chen L.C., Hsueh C., Tsang N.M., Liang Y., Chang K.P., Hao S.P., Yu J.S., Chang Y.S. Heterogeneous ribonucleoprotein K and thymidine phosphorylase are independent prognostic and therapeutic markers for nasopharyngeal carcinoma. Clin. Cancer Res. 2008, 14:3807-3813.
87. Barboro P., Salvi S., Rubagotti A., Boccardo S., Spina B., Truini M., Carmignani G., Introini C., Ferrari N., Boccardo F., Balbi C. Prostate cancer: prognostic significance of the association of heterogeneous nuclear ribonucleoprotein K and androgen receptor expression. Int. J. Oncol. 2014, 44:1589-1598.
88. Guo Y., Zhao J., Bi J., Wu Q., Wang X., Lai Q. Heterogeneous nuclear ribonucleoprotein K (hnRNP K) is a tissue biomarker for detection of early hepatocellular carcinoma in patients with cirrhosis. J. Hematol. Oncol. 2012, 5:37.
89. Inoue A., Sawata S.Y., Taira K., Wadhwa R. Loss-of-function screening by randomized intracellular antibodies: identification of hnRNP-K as a potential target for metastasis. Proc. Natl. Acad. Sci. USA 2007, 104:8983-8988.
90. Gao R., Yu Y., Inoue A., Widodo N., Kaul S.C., Wadhwa R. Heterogeneous nuclear ribonucleoprotein K (hnRNP-K) promotes tumor metastasis by induction of genes involved in extracellular matrix, cell movement, and angiogenesis. J. Biol. Chem. 2013, 288:15046-15056.
91. Benelli R., Monteghirfo S., Balbi C., Barboro P., Ferrari N. Novel antivascular efficacy of metronomic docetaxel therapy in prostate cancer: hnRNP K as a player. Int. J. Cancer 2009, 124:2989-2996.
92. Ricci F., Rubagotti A., Zinoli L., Mangerini R., Nuzzo P.V., Carmignani G., Simonato A., Barboro P., Balbi C., Boccardo F. Prognostic value of nuclear matrix protein expression in localized prostate cancer. J. Cancer Res. Clin. Oncol. 2012, 138:1379-1384.
93. Wang L.G., Johnson E.M., Kinoshita Y., Babb J.S., Buckley M.T., Liebes L.F., Melamed J., Liu X.M., Kurek R., Ossowski L., Ferrari A.C. Androgen receptor overexpression in prostate cancer linked to Purα loss from a novel repressor complex. Cancer Res. 2008, 68:2678-2688.
94. Mukhopadhyay N.K., Kim J., Cinar B., Ramachandran A., Hager M.H., Di Vizio D., Adam R.M., Rubin M.A., Raychaudhuri P., De Benedetti A., Freeman M.R. Heterogeneous nuclear ribonucleoprotein K is a novel regulator of androgen receptor translation. Cancer Res. 2009, 69:2210-2218.
95. Barboro P., Repaci E., Ferrari N., Rubagotti A., Boccardo F., Balbi C. Androgen receptor and heterogeneous nuclear ribonucleoprotein K colocalize in the nucleoplasm and are modulated by bicalutamide and 4-hydroxy-tamoxifen in prostatic cancer cell lines. Prostate 2011, 71:1466-1479.
96. Barboro P., Borzì L., Repaci E., Ferrari N., Balbi C. Androgen receptor activity is affected by both nuclear matrix localization and the phosphorylation status of the heterogeneous nuclear ribonucleoprotein K in anti-androgen-treated LNCaP cells. PLoS ONE 2013, 8:e79212.
97. Grobholz R., Griebe M., Sauer C.G., Michel M.S., Trojan L., Bleyl U. Influence of neuroendocrine tumor cells on proliferation in prostatic carcinoma. Hum. Pathol. 2005, 36:562-570.
98. Ciarlo M., Benelli R., Barbieri O., Minghelli S., Barboro P., Balbi C., Ferrari N. Regulation of neuroendocrine differentiation by AKT/hnRNPK/AR/β-catenin signaling in prostate cancer cells. Int. J. Cancer 2012, 131:582-590.
99. Perrotti D., Calabretta B. Post-transcriptional mechanisms in BCR/ABL leukemogenesis: role of shuttling RNA-binding proteins. Oncogene 2002, 21:8577-8583.
100. McCubrey J.A., Steelman L.S., Chappell W.H., Abrams S.L., Wong E.W., Chang F., Lehmann B., Terrian D.M., Milella M., Tafuri A., Stivala F., Libra M., Basecke J., Evangelisti C., Martelli A.M., Franklin R.A. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim. Biophys. Acta 2007, 1773:1263-1284.
101. Chen L.C., Liu H.P., Li H.P., Hsueh C., Yu J.S., Liang C.L., Chang Y.S. Thymidine phosphorylase mRNA stability and protein levels are increased through ERK-mediated cytoplasmic accumulation of hnRNP K in nasopharyngeal carcinoma cells. Oncogene 2009, 28:1904-1915.
102. Qi Z., Takamatsu H., Espinoza J.L., Lu X., Sugimori N., Yamazaki H., Okawa K., Nakao S. Autoantibodies specific to hnRNP K: a new diagnostic marker for immune pathophysiology in aplastic anemia. Ann. Hematol. 2010, 89:1255-1263.
103. Mojtahedi Z., Safaei A., Yousefi Z., Ghaderi A. Immunoproteomics of HER2-positive and HER2-negative breast cancer patients with positive lymph nodes. OMICS 2011, 15:409-418.